• Lung Cancer—clinical treatment, prevention and biology
• T-cell lymphomas-staging, treatment and biology
• Growth factors and intracellular signal transduction
• Drug Development

• Flow cytometry, DNA content, intracellualr ions (eg. calcium and pH), antisense and gene therapy preclinical imaging and treatment studies with human cancer cell lines in vitro and in nude mice and rats.

• Chan DC, Geraci M, Bunn PA Jr: Anti-growth factor therapy for lung cancer. Drug Resistance Updates 1:377-388, 1998.

• Beckman A, Helfrich B, Bunn PA, Heasely LE: Expression of catalytically inactive phospholipase Cb disrupts the phospholipase Cb and mitogen activated protein kinase signalling and inhibits small cell lung cancer growth. Cancer Res 58: 910-913, 1998

• Stewart JM, Gera L, York EJ, Chan DC, Bunn P: Bradykinin antagonists: present progress and future prospects. Immunopharmacol. 43:155-61, 1998.

• Kelly K, Hazuka P, Pan Z, Murphy J, Caskey J, Leonard C, Bunn PA Jr: A phase I study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation in patients with regionally inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phy. 40:559-67, 1998.

• Bunn PA Jr, Helfrich BA, Brenner DG, Chan DC, Dykes DJ, Cohen AJ, Miller YE: Effects of recombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo. Clin Cancer Res. 95:2849-58, 1998.

• Bunn PA, Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 5:1087-1100, 1998.

• Chan DC, Geraci M, Bunn PA Jr: Anti-growth factor therapy for lung cancer. Drug Resistance Updates 1:377-388, 1998.

• Beckman A, Helfrich B, Bunn PA, Heasely LE: Expression of catalytically inactive phospholipase Cb disrupts the phospholipase Cb and mitogen activated protein kinase signalling and inhibits small cell lung cancer growth. Cancer Res 58: 910-913, 1998.

• Bunn PA Jr, Vokes EE, Langer CJ, Schiller JH. An update on North American randomized studies in non-small cell lung cancer. Semin Oncol. 25(4 Suppl):2-10, 1998.

• Kelly K, Bunn PA Jr. Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer. 20:85-91, 1998.

• Schefer H, and Bunn PA Jr.: To treat or not to treat metastatic non-small-cell lung cancer: still an ethical dilemma? Oncology Nurses Today 3:No.2, 1998.

• Bunn PA Jr., LeChevalier T: Lung cancer research: new combinations and the emerging role of gemcitabine. Semin. Oncol. 24: 1, 1998.

• Bunn PA Jr., Vokes EE, Langer CJ, Schiller JH: An update on North American randomized studies in non-small cell lung cancer. Semin. Oncol. 25: 2-10, 1998.

• Bunn PA Jr., Triplet chemotherapy combinations with new agents: is there a rational? Semin. Oncol. 25: 55-61, 1998.

• Ahnen DA, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA Jr., Stemmerman G, Wells JD, Macdonald JS, and Meyskens FL, Jr. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A southwest oncology group study. Cancer Res. 58:1149-1158, 1998.

• Bunn PA Jr., Soriano AR: Chemotherapeutic Options in Lung Cancer, Cancer, 83:1740-1750, 1998.

• Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA, Chou TC: Synergistic effects of new chemoprentitive and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59: 6178-6184, 1999.

• Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA Jr: A phase I study of paclitaxel, etoposide, and cisplatin in extensive small cell lung cancer. Clin Cancer Res 5:3419-24, 1999.

• Bunn PA Jr. Update on Lung Cancer SPORE activity in the US. Lung Cancer. 25:226-7,1999

• Bunn PA Jr. Immune therapy for lung cancer: are we getting closer? Am J Respir Cell Mol Biol. 21:10-2, 1999.

• Bunn PA Jr. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer. Semin Oncol. 26(1 Suppl):25-30, 1999.

• Bunn PA Jr.: The emerging role of paclitaxel plus carboplatin in non-small-cell lung cancer. Oncol. Suppl 4: 35-41, 1999.

• Ginsberg R, Bunn PA Jr., Keller: New approaches for the treatment of resectable non-small-cell lung cancer. From Research to Practice 1: 13-19, 1999.

• Bunn PA Jr.: The emerging role of paclitaxel plus carboplatin in non-small-cell lung cancer. Oncol. Suppl 4: 35-41, 1999.

• Calvo R, West J, Franklin W, Erickson P, Bemis L, Li E, Helfrich B, Bunn P, Roche J, Brambilla E, Rosell R, Gemmill RM, Drabkin HA. Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci USA. 97(23):12776-81, 2000.

• Agus D, Bunn PA Jr, Franklin W, Garcia M, Ozols R. Her-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer and ovarian cancer. Sem Oncol. 27 (Suppl 11):53-63, 2000.

• Bunn PA Jr, Soriano A, Johnson G, Heasley L. New therapeutic strategies for lung cancer: biology and molecular biology come of age. Chest. 117(4 Suppl):163S-168S, 2000.

• Wood ME, Kelly K, Mullineaux LG, Bunn PA Jr: The inherited naature of lung cancer: a pilot study. Lung Cancer. 30: 135-144, 2000.

• Kelly K, Mikhaeel-Kamel N, Pan Z, Murphy J, Prindiville S, Bunn PA Jr.: A phase I/II trial of paclitaxel, carboplatin and gemcitabine in untreated patients with advanced non-small cell cancer. Clin Cancer Res. 6(9): 3474-3479, 2000

• Bunn PA Jr, Kelly K. New combinations in the treatment of lung cancer: a time for optimism. Chest. 117(4 Suppl):138S-143S, 2000.

• Bunn PA Jr, Mault J, Kelly K. Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer: a time for reassessment? Chest. 117(4 Suppl): 119S-122S, 2000.

• Pisters KM, Ginsberg RJ, Giroux DJ, Putnam JB Jr, Kris MG, Johnson DH, Roberts JR, Mault J, Crowley JJ, Bunn PA Jr. Induction of chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg. 119:429-39, 2000.

• Hirsch FR, Franklin WA, Gazdar AF, Bunn PA Jr: Early detection of lung cancer; clinical perspectives of recent advances in biology and radiology. Clin Cancer Res 7:5-22, 2001.

• Stewart JM, Gera L, York EJ, Chan DC, Whalley EJ, Bunn PA Jr, Vavrek RJ. Metabolism-resistant bradykinin antagonists: development and application. Biol Chem 382:37-41, 2001.

• Bunn PA Jr. Triplet combination chemotherapy and targeted therapy regimens for the treatment of advanced non-small cell lung cancer. Oncology 15(Suppl 6):26-32, 2001.

• Postmus PE, Bunn PA Jr: Alimta as a single agent in the therapy of advanced lung cancer. Sem Oncol (In press), 2001.

• Kelly K, Crowley J, Bunn PA Jr. Presant CA, Grevstad PK, Wozniak AJ, Weiss, GR, Moore DF, Israel VK, Livingston RB, Gandara DR. A randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol. In press, 2001.

• Editorial Boards
• Cancer Research
• Lung Cance
• International Journal of Oncology
• Oncology Times
• Clinical Cancer Research
• President-Elect American Society of Clinical Oncology
• Past President, Association of American Cancer Institutes

We have preclinical models for lung cancer to study various growth factors on the growth of human lung cancers. We are synthesizing and evaluating the effects of monoclonal antibodies, peptide antagonists and other agents on the growth of lung cancer cells. We are evaluating the utility of a variety of small molecules, which inhibit signal transduction for the prevention, and treatment of lung cancers. We are evaluating the ability of several agents to overcome drug resistance in lung cancer.

  To top of page